000			03423na a2200349 4500
003			H12O
005			20210706062655.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCruz Bértolo, Javier de la _91783 _eEpidemiología Clínica
100			_91250 _aDelgado Jiménez, Juan Francisco _eCardiología
100			_aGómez Sánchez, Miguel Ángel _91237 _eCardiología
100			_aGuadalix Iglesias, Sonsoles _9820 _eEndocrinología y Nutrición
100			_9501 _aHawkins Carranza, Federico Gustavo _eEndocrinología y Nutrición
100			_9821 _aLora Pablos, David _eInstituto Investigación I+12
100			_aMartínez Díaz-Guerra, Guillermo _9760 _eEndocrinología y Nutrición
100			_aVara Paniagua, Jesús María _91992 _eMedicina Física y Rehabilitación
245	0	0	_aBone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3. _h[artículo]
260			_bProgress in Transplantation , _c2012
300			_a22(3):237-43.
500			_aFormato Vancouver: Gilfraguas L, Guadalix S, Martínez G, Jodar E, Vara J, Gómez-Sánchez MA, Delgado J, De La Cruz J, Lora D, Hawkins F. Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3. Prog Transplant. 2012 Sep;22(3):237-43.
501			_aPMID: 22951500
504			_aContiene 28 referencias
520			_aOBJECTIVE: To compare the effects of calcitonin, etidronate, and alendronate in preventing bone loss during the first 2 years after heart transplant. METHODS: A total of 222 heart transplant recipients (mean [SD] age, 52.4 [10] years, 85% male) were evaluated. Patients with normal bone mineral density (reference group, n = 102) received 1000 mg/d calcium plus 800 IU/d vitamin D3. The rest were assigned to 200 IU/d of calcitonin (n=42), 400 mg/d etidronate orally for 14 days quarterly (n = 33), or 10 mg/d alendronate (n = 45). All patients received calcium and vitamin D. Bone mineral density was assessed by dual-energy x-ray absorptiometry in the lumbar spine, the entire femur, and the femoral neck at baseline and 6, 12, and 24 months after transplant. RESULTS: At 2 years after transplant, bone mineral density in the lumbar spine had decreased in the reference group (-3.07%), calcitonin group (-0.93%), and etidronate group (-1.87%) but not in the alendronate group (+4.9%; P <.001). After 2 years, bone mineral density in the entire femur decreased in all groups (-3.2% in the reference group, -3.6% in the calcitonin group, -4.6% in the etidronate group, and -0.5% in the alendronate group) but bone loss was significantly lower in the alendronate group (P <.001). Bone mineral density in the femoral neck also decreased in all groups. The incidence of vertebral fractures did not differ among groups. Adverse events were similar between groups. CONCLUSIONS: Alendronate therapy in heart transplant recipients was associated with a significant increase in bone mineral density in the lumbar spine and less bone loss at the hip.
710			_9292 _aServicio de Endocrinología y Nutrición
710			_9119 _aServicio de Cardiología
710			_9402 _aServicio de Medicina Física y Rehabilitación
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/8/pc8386.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c8386 _d8386